An Open Label, Single Arm Phase 1b Study Of Avelumab Plus Axitinib As First Line Treatment In Patients With Advanced Hepatocellular Carcinoma

Next Previous
Trial Profile

An Open Label, Single Arm Phase 1b Study Of Avelumab Plus Axitinib As First Line Treatment In Patients With Advanced Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Avelumab (Primary) ; Axitinib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Pfizer

    • Most Recent Events

    • 25 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top